Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7771]

Probing the mechanism of ADAM28-mediated cancer metastasis

Probing the mechanism of ADAM28-mediated cancer metastasis

Kinase targets and anti-targets in cancer poly-pharmacology

Kinase targets and anti-targets in cancer poly-pharmacology

Experimental combination for stomach and oesophageal cancer

Experimental combination for stomach and oesophageal cancer

Carfilzomib demonstrates efficacy as new frontline treatment regimen for multiple myeloma

Carfilzomib demonstrates efficacy as new frontline treatment regimen for multiple myeloma

ASCO 2012: New MEK inhibitor, trametinib, improves survival in advanced melanoma

ASCO 2012: New MEK inhibitor, trametinib, improves survival in advanced melanoma

ASCO 2012: Duloxetine, a serotonin-norepinephrine reuptake inhibitor anti-depressant, is first effective treatment for chemotherapy-induced peripheral neuropathy

ASCO 2012: Duloxetine, a serotonin-norepinephrine reuptake inhibitor anti-depressant, is first effective treatment...

ASCO 2012: Afatinib delays progression of advanced lung adenocarcinomas, particularly in genetic subset of tumours

ASCO 2012: Afatinib delays progression of advanced lung adenocarcinomas, particularly in genetic subset of tumours

ASCO 2012: Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Newer, more costly drugs no better than standard weekly paclitaxel as first line therapy for locally advanced or metastatic breast cancer

ASCO 2012: Newer, more costly drugs no better than standard weekly paclitaxel as first line therapy for locally...

ASCO 2012: New BRAF inhibitor dabrafenib delays disease progression better than standard chemotherapy in patients with advanced melanoma

ASCO 2012: New BRAF inhibitor dabrafenib delays disease progression better than standard chemotherapy in patients...

More from ecancer